Top Markets
#1 B3 (Base) B3 (Base) +68.61%
#2 Chainbase Chainbase +49.84%
#3 Stargate Finance Stargate Finance +25.33%
#4 Kyber Network Crystal Kyber Network Crystal +23.06%
#5 Liquid Mercury Liquid Mercury +20.08%
#6 Block Street Block Street +16.15%
#7 Trusta AI Trusta AI +12.43%
#8 BabyBoomToken BabyBoomToken +11.40%
#9 PlaysOut PlaysOut +10.18%
#10 MEMEX Token MEMEX Token +9.89%
Coin of the day
B3 (Base) B3 (Base)
Tetapan
Bahasa
MALAY
Mata wang
USD
Tema
Bristol-Myers Squibb Company Bristol-Myers Squibb Company

Bristol-Myers Squibb Company

BMY
Kedudukan dalam Saham #149
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and... Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.
Harga Saham
$59.43
Modal Pasaran
$121.03B
Perubahan (1 hari)
0.83%
Perubahan (1 tahun)
0.90%
Negara
US
Perdagangan Bristol-Myers Squibb Company (BMY)

Kategori

Healthcare
Nisbah P/S bagi Bristol-Myers Squibb Company (BMY)
Nisbah P/S pada March 2026 TTM: 2.50
Menurut laporan kewangan dan harga saham terkini Bristol-Myers Squibb Company, nisbah P/S semasa (TTM) ialah 2.50. Pada akhir 2024, nisbah P/S syarikat ialah 2.37.
Sejarah nisbah P/S untuk Bristol-Myers Squibb Company dari 2000 hingga 2026
Nisbah P/S pada akhir setiap tahun
Tahun Nisbah P/S Ubah
2026 (TTM) 2.50 9.50%
2025 2.28 -3.76%
2024 2.37 0.63%
2023 2.36 -28.95%
2022 3.32 11.21%
2021 2.99 -9.37%
2020 3.29 -21.30%
2019 4.19 11.26%
2018 3.76 -22.46%
2017 4.85 -3.48%
2016 5.03 -27.41%
2015 6.92 12.42%
2014 6.16 15.51%
2013 5.33 72.66%
2012 3.09 9.53%
2011 2.82 21.13%
2010 2.33 -12.15%
2009 2.65 18.75%
2008 2.23 -17.35%
2007 2.70 -6.23%
2006 2.88 23.31%
2005 2.34 -9.03%
2004 2.57 -3.17%
2003 2.65 3.91%
2002 2.55 -49.91%
2001 5.09 -32.92%
2000 7.59 0.00%
Nisbah P/S untuk syarikat atau pesaing yang serupa
Syarikat Nisbah P/S Perbezaan Nisbah P/S Negara
Eli Lilly Eli Lilly
Eli Lilly
LLY.US
14.26 471.10%
US
AstraZeneca PLC AstraZeneca PLC
AstraZeneca PLC
AZN.US
4.96 98.72%
GB
Johnson & Johnson Johnson & Johnson
Johnson & Johnson
JNJ.US
6.18 147.51%
US
AbbVie Inc. AbbVie Inc.
AbbVie Inc.
ABBV.US
6.35 154.40%
US
Novartis AG Novartis AG
Novartis AG
NVS.US
5.18 107.35%
CH